Comparing the current results to its competitors, Apyx Medical reported Revenue increase in the 2 quarter 2026 by 25.27 % year on year. The sales growth was above Apyx Medical's competitors' average revenue growth of 11.25 %, achieved in the same quarter.
Apyx Medical's Comment on Competition and Industry Peers
The company has established an intellectual property portfolio comprising 41 U.S. patents, 61 foreign patents, and multiple pending patent and trademark applications. It recognizes the risk of patent infringement or the development of similar or non-infringing products by competitors. The company manufactures most of its products in Clearwater, Florida, and Sofia, Bulgaria. These facilities are certified under ISO13485:2016 and undergo FDA and other regulatory inspections to maintain quality and compliance.
August 9, 2024
In the rapidly evolving field of cosmetic surgery, where advancements in technology can define operational success and patient outcomes, Apyx Medical Corporation has made a significant leap forward. The company recently announced the publication of a peer-reviewed clinical study, featured in the journal Plastic and Reconstructive Surgery Global Open, which compares its proprietary helium plasma and radiofrequency platform technology, known as Renuvion, to another established technology InMode s Bipolar RF system. This innovative research provides a crucial understanding of how emerging technologies can enhance outcomes for patients undergoing liposuction and body contouring procedures. Understanding the Tech...
Anika Therapeutics Inc is a medical technology company that focuses on developing and commercializing therapeutic products to treat tissue-related disorders. Their business model revolves around conducting extensive research and development to create innovative therapies, partnering with healthcare professionals and distributors to bring their products to market, and generating revenue through the sale of these products worldwide. They also collaborate with other companies and academic institutions to enhance their product portfolio and expand their reach in the healthcare industry.
Nuo Therapeutics Inc's business model revolves around developing and commercializing innovative biologic therapies aimed at improving healthcare outcomes for patients. They focus on the research, development, and marketing of new therapeutic products, primarily in the wound care sector.
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Orthopediatrics Corp is a medical device company specializing in orthopedic implants and instruments for children with orthopedic conditions. Their business model revolves around designing, manufacturing, and distributing innovative pediatric orthopedic products to healthcare providers worldwide. By focusing solely on pediatric patients, they aim to address the unique needs and challenges in this niche market, providing quality solutions for improved pediatric orthopedic care.
Sources:
Apyx Medical Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Apyx Medical Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
